about
Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cellsVorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell modelsOxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.MiR-200c regulates Noxa expression and sensitivity to proteasomal inhibitors.Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideCIP2A is a target of bortezomib in human triple negative breast cancer cells.Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death.Cancer Tissue Engineering: A Novel 3D Polystyrene Scaffold for In Vitro Isolation and Amplification of Lymphoma Cancer Cells from Heterogeneous Cell Mixtures.Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.Recruitment of APPL1 to ubiquitin-rich aggresomes in response to proteasomal impairment.P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
P2860
Q24298561-443B36A3-3AF7-4563-9F9D-20278A5F6255Q33620173-BC515CA7-31EA-4AB5-9AC9-E23545C4EC24Q33741142-E294284A-DA79-4F06-9E67-277FA24F672BQ33832937-1A38027F-A028-4657-A12F-D46F88066792Q34277271-6DCC6605-2E06-42CF-B8F8-BA80F6FD87B9Q35128130-5727DCBF-18DA-407B-ABA0-B93CE0D0721FQ35836881-0D3A9852-052D-4F62-B13E-6761DEC0DCB9Q35989980-889A5FE1-3E00-46E6-BB3A-9DC1F6798F6AQ36245640-2166EC0C-412B-45C5-ABBB-829144794F39Q37672026-7979A475-0A38-4A00-BC6F-21AF478DEA0BQ38342904-5D81E106-DC0C-43BE-AE49-E7F04C1CBB25Q38864150-4FBB1645-22B4-46B1-896C-D18A3B5E2A5EQ39414811-B220DDF0-1F69-443F-8C4D-465392F6A75EQ41853365-9C5CAABC-FDF6-4268-9C77-7F164D1EF1C8Q48943059-1D23C93D-CD75-4F8D-A74A-0363D27AB176Q50128397-9FFB7F10-02D4-48F7-BCFE-9EB82F906D84
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bortezomib in mantle cell lymphoma.
@en
Bortezomib in mantle cell lymphoma.
@nl
type
label
Bortezomib in mantle cell lymphoma.
@en
Bortezomib in mantle cell lymphoma.
@nl
prefLabel
Bortezomib in mantle cell lymphoma.
@en
Bortezomib in mantle cell lymphoma.
@nl
P2860
P356
P1433
P1476
Bortezomib in mantle cell lymphoma.
@en
P2093
K Stephen Suh
P2860
P304
P356
10.2217/14796694.4.2.149
P407
P577
2008-04-01T00:00:00Z